Lantheus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Lantheus and other ETFs, options, and stocks.

About LNTH

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. 

CEO
Mary Anne Heino
CEOMary Anne Heino
Employees
1,193
Employees1,193
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
1956
Founded1956
Employees
1,193
Employees1,193

LNTH Key Statistics

Market cap
7.16B
Market cap7.16B
Price-Earnings ratio
26.50
Price-Earnings ratio26.50
Dividend yield
Dividend yield
Average volume
1.08M
Average volume1.08M
High today
$111.00
High today$111.00
Low today
$108.00
Low today$108.00
Open price
$109.92
Open price$109.92
Volume
511.08K
Volume511.08K
52 Week high
$111.86
52 Week high$111.86
52 Week low
$47.25
52 Week low$47.25

Stock Snapshot

As of today, Lantheus(LNTH) shares are valued at $109.89. The company's market cap stands at 7.16B, with a P/E ratio of 26.50.

On 2026-07-05, Lantheus(LNTH) stock traded between a low of $108.00 and a high of $111.00. Shares are currently priced at $109.89, which is +1.8% above the low and -1.0% below the high.

Lantheus(LNTH) shares are trading with a volume of 511.08K, against a daily average of 1.08M.

In the last year, Lantheus(LNTH) shares hit a 52-week high of $111.86 and a 52-week low of $47.25.

In the last year, Lantheus(LNTH) shares hit a 52-week high of $111.86 and a 52-week low of $47.25.

LNTH News

Simply Wall St 2d
Did FDA’s Facility-Related LNTH-2501 Delay and Russell Additions Just Reframe Lantheus Holdings’ Risk Profile?

In late June 2026, Lantheus Holdings reported that the FDA issued a Complete Response Letter for its LNTH-2501 PET imaging kit for somatostatin receptor‑positiv...

Did FDA’s Facility-Related LNTH-2501 Delay and Russell Additions Just Reframe Lantheus Holdings’ Risk Profile?
Benzinga 6d
FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit

FDA Issues Complete Response Letter For Lantheus Imaging Agent The FDA stated unresolved third-party facility manufacturing-related conditions. The third-part...

FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit
Simply Wall St 6d
Lantheus Holdings New Product Narrative Keeps Valuation Questions In Focus

Lantheus Holdings (LNTH) has drawn fresh attention after recent share price moves, with the stock closing at $109.80. Investors are reassessing what the company...

Lantheus Holdings New Product Narrative Keeps Valuation Questions In Focus

Analyst ratings

79%

of 14 ratings
Buy
78.6%
Hold
14.3%
Sell
7.1%

People also own

Based on the portfolios of people who own LNTH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.